文献速递肿瘤 PET/CT

18F标记D肽拮抗剂用于PD-L1状态PET显像的临床前与首次人体评估

Preclinical and first-in-human evaluation of 18F-labeled D-peptide antagonist for PD-L1 status imaging with PET.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-07-14

本研究报道了一种新型18F标记D肽拮抗剂18F-NOTA-NF12,用于PD-L1状态的PET显像。临床前研究显示该探针在MC38和H1975肿瘤中可清晰显像,肿瘤/肌肉比值分别为5.36±1.17和7.13±1.78(注射后60分钟),且肿瘤摄取与PD-L1表达相关。在非小细胞肺癌和食管癌患者中证实了该探针对PD-L1显像的特异性,高PD-L1表达患者中18F-NOTA-NF12 PET/CT与18F-FDG PET/CT表现相当。

要点

  • 18F-NOTA-NF12手动和自动放射合成产率分别为41.7±10.2%和70.6±4.2%。
  • 体外结合实验显示高特异性和亲和力,IC50为78.35 nM,KD为85.08 nM。
  • 注射后60分钟MC38和H1975肿瘤的肿瘤/肌肉比值分别为5.36±1.17和7.13±1.78。

核心结论

  • 18F-NOTA-NF12被成功开发为PD-L1特异性示踪剂,在临床前和首次人体试验中显示出有前景的结果,支持进一步验证其用于临床环境中PD-L1状态的PET显像。

研究设计与样本

  • 研究包括手动和自动放射合成、细胞摄取和结合实验(MC38、H1975和A549细胞系)、临床前模型中的显像能力/生物分布/药代动力学研究,以及在健康志愿者和患者中评估安全性、辐射剂量学、生物分布和PD-L1显像潜力。

主要发现

  • 18F-NOTA-NF12手动和自动放射合成产率分别为41.7±10.2%和70.6±4.2%。
  • 体外结合实验显示高特异性和亲和力,IC50为78.35 nM,KD为85.08 nM。
  • 注射后60分钟MC38和H1975肿瘤清晰显像,肿瘤/肌肉比值分别为5.36±1.17和7.13±1.78。
  • 吉西他滨和司美替尼诱导的PD-L1动态变化可通过18F-NOTA-NF12监测,肿瘤摄取与其PD-L1表达相关性良好。
  • 18F-NOTA-NF12经肾脏排泄,从血液和其他非特异性器官快速清除,有助于在临床时间范围内实现高对比度显像;在非小细胞肺癌和食管癌患者中证实了其对PD-L1显像的特异性,高PD-L1表达患者中18F-NOTA-NF12 PET/CT与18F-FDG PET/CT表现相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: PD-L1 PET imaging allows for the whole body measuring its expression across primary and metastatic tumors and visualizing its spatiotemporal dynamics before, during, and after treatment. In this study, we reported a novel 18F-labeled D-peptide antagonist, 18F-NOTA-NF12, for PET imaging of PD-L1 status in preclinical and first-in-human studies. METHODS: Manual and automatic radiosynthesis of 18F-NOTA-NF12 was performed. Cell uptake and binding assays were completed in MC38, H1975, and A549 cell lines. The capacity for imaging of PD-L1 status, biodistribution, and pharmacokinetics were investigated in preclinical models. The PD-L1 status was verified by western blotting, immunohistochemistry/fluorescence, and flow cytometry. The safety, radiation dosimetry, biodistribution, and PD-L1 imaging potential were evaluated in healthy volunteers and patients. RESULTS: The radiosynthesis of 18F-NOTA-NF12 was achieved via manual and automatic methods with radiochemical yields of 41.7 ± 10.2 % and 70.6 ± 4.2 %, respectively. In vitro binding assays demonstrated high specificity and affinity with an IC50 of 78.35 nM and KD of 85.08 nM. The MC38 and H1975 tumors were clearly visualized with the optimized tumor-to-muscle ratios of 5.36 ± 1.17 and 7.13 ± 1.78 at 60 min after injection. Gemcitabine- and selumetinib-induced modulation of PD-L1 dynamics was monitored by 18F-NOTA-NF12. The tumor uptake correlated well with their PD-L1 expression. 18F-NOTA-NF12 exhibited renal excretion and rapid clearance from blood and other non-specific organs, contributing to high contrast imaging in the clinical time frame. In NSCLC and esophageal cancer patients, the specificity of 18F-NOTA-NF12 for PD-L1 imaging was confirmed. The 18F-NOTA-NF12 PET/CT and 18F-FDG PET/CT had equivalent findings in patients with high PD-L1 expression. CONCLUSION: 18F-NOTA-NF12 was developed successfully as a PD-L1-specific tracer with promising results in preclinical and first-in-human trials, which support the further validation of 18F-NOTA-NF12 for PET imaging of PD-L1 status in clinical settings.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhou M, Wang X, Chen B, et al. Preclinical and first-in-human evaluation of 18F-labeled D-peptide antagonist for PD-L1 status imaging with PET. Eur J Nucl Med Mol Imaging. 2022. PMID: 35831714. doi:10.1007/s00259-022-05876-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。